Dr. Camidge on the ALTA Study of Brigatinib in NSCLC

D. Ross Camidge, MD, PhD
Published: Monday, Oct 16, 2017



D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the results of the phase II ALTA trial, which is exploring brigatinib (Alunbrig) in crizotinib (Xalkori)-refractory patients with ALK-positive non–small cell lung cancer, during an interview at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.

There is now an embarrassment of riches regarding ALK inhibitors, one of which is brigatinib, Camidge explains. In the ALTA trial, 2 doses of brigatinib were explored: 90 mg and 180 mg, the latter of which was given after 7 days of the 90-mg dose of brigatinib. The median progression-free survival (PFS) with the 90-mg dose is about 9 months; however, the 180-mg dose with the median PFS is now over 16 months, Camidge says. 

Now, Camidge questions whether these findings will translate into better efficacy when used in the first-line setting.

<<< View more from the World Conference on Lung Cancer


D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the results of the phase II ALTA trial, which is exploring brigatinib (Alunbrig) in crizotinib (Xalkori)-refractory patients with ALK-positive non–small cell lung cancer, during an interview at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.

There is now an embarrassment of riches regarding ALK inhibitors, one of which is brigatinib, Camidge explains. In the ALTA trial, 2 doses of brigatinib were explored: 90 mg and 180 mg, the latter of which was given after 7 days of the 90-mg dose of brigatinib. The median progression-free survival (PFS) with the 90-mg dose is about 9 months; however, the 180-mg dose with the median PFS is now over 16 months, Camidge says. 

Now, Camidge questions whether these findings will translate into better efficacy when used in the first-line setting.

<<< View more from the World Conference on Lung Cancer

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x